Latest Safety News

Avecho Biotechnology reported a 9.3% revenue increase alongside a 41.5% rise in net loss for 2025, while progressing its Phase III CBD insomnia trial and securing a significant licensing agreement with Sandoz.

Radiopharm Theranostics reported a 44% increase in net loss to $27 million for the half-year ended December 2025, driven by expanded R&D spending. The company bolstered its cash reserves through a $35 million placement while progressing multiple clinical trials across its radiopharmaceutical pipeline.

Actinogen Medical has successfully completed a $16.8 million capital raising, combining a $12 million placement with a $4.8 million share purchase plan, to fund its pivotal Alzheimer’s disease trial and other 2026 initiatives.

Challenger Gold has initiated ore haulage from its Hualilán Mine to the Casposo Plant, marking a pivotal step in its toll milling strategy aimed at near-term production and cash flow. The company also reports robust resource and reserve updates alongside key infrastructure advancements.

Metals X Limited reported a robust 2025 financial year with revenue up 30% to $285 million, driven by higher tin prices despite a slight dip in production. The company is advancing its key growth project, Rentails, targeting a final investment decision in late 2026.

Polymetals Resources has reported its maiden revenue from the Endeavor Mine with first concentrate shipments, yet posted a substantial half-year loss of $34.5 million. Operational setbacks and exploration advances mark a pivotal phase for the company.

TPG Telecom reported a robust FY25 with strategic asset sales, a major network sharing deal, and a $3 billion capital return, underpinning strong financial and sustainability progress.

Paradigm Biopharmaceuticals reports a sharp rise in half-year losses as it intensifies investment in its pivotal Phase 3 trial for knee osteoarthritis, setting sights on a critical interim analysis in mid-2026. The company also expands its osteoarthritis pipeline and maintains strong funding amid a strengthening biotech sector.

Veris Ltd reports a solid 9% revenue increase in H1 FY26, driven by a strategic pivot to higher-value digital and spatial advisory services, with underlying profits up 69%.

icetana Limited reports a strong first half of 2026 with recurring revenue up 43%, driven by key partnerships and expanded market reach across APAC and the Middle East.

GreenHy2 Limited narrowed its net loss by 16% in FY2025, driven by government grants and initial sales of its new sodium-ion batteries. Strategic partnerships and product diversification position the company for growth in renewable energy storage.

Atlas Pearls reports a challenging first half of FY26 with a 27% drop in revenue and a net loss of $5.2 million, driven by weaker market demand and a shift towards lower-grade pearl sales.